Jiangsu Jibeier Pharmaceutical Co Ltd (688566) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.005x

Based on the latest financial reports, Jiangsu Jibeier Pharmaceutical Co Ltd (688566) has a cash flow conversion efficiency ratio of 0.005x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥11.07 Million ≈ $1.62 Million USD) by net assets (CN¥2.37 Billion ≈ $346.78 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 688566 market cap for the company's overall valuation and market capitalisation.

Jiangsu Jibeier Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how Jiangsu Jibeier Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Jiangsu Jibeier Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Jiangsu Jibeier Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Explore how high is Jiangsu Jibeier Pharmaceutical Co Ltd's earnings quality to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Kardemir Karabuk Demir Celik Sanayi ve Ticaret AS Class D
IS:KRDMD
0.031x
Peapack-Gladstone Financial
NASDAQ:PGC
0.072x
Zhejiang Zhaofeng Mechanical and Electronic Co Ltd
SHE:300695
0.000x
Kopin Corporation
NASDAQ:KOPN
-0.063x
Sichuan Huiyu Pharmaceutical Co Ltd
SHG:688553
0.016x
Thungela Resources Limited
JSE:TGA
0.156x
International Tower Hill Mines Ltd
TO:ITH
0.010x
New York Mortgage Trust, Inc.
NASDAQ:ADAM
-0.011x

Annual Cash Flow Conversion Efficiency for Jiangsu Jibeier Pharmaceutical Co Ltd (2016–2025)

The table below shows the annual cash flow conversion efficiency of Jiangsu Jibeier Pharmaceutical Co Ltd from 2016 to 2025. View 688566 live share price for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 CN¥2.45 Billion
≈ $358.46 Million
CN¥248.30 Million
≈ $36.33 Million
0.101x +6.11%
2024-12-31 CN¥2.25 Billion
≈ $329.81 Million
CN¥215.29 Million
≈ $31.50 Million
0.096x +14.41%
2023-12-31 CN¥1.91 Billion
≈ $279.55 Million
CN¥159.50 Million
≈ $23.34 Million
0.083x -6.15%
2022-12-31 CN¥1.69 Billion
≈ $247.93 Million
CN¥150.72 Million
≈ $22.06 Million
0.089x -4.97%
2021-12-31 CN¥1.61 Billion
≈ $235.34 Million
CN¥150.56 Million
≈ $22.03 Million
0.094x +25.73%
2020-12-31 CN¥1.58 Billion
≈ $230.67 Million
CN¥117.36 Million
≈ $17.17 Million
0.074x -69.66%
2019-12-31 CN¥470.46 Million
≈ $68.84 Million
CN¥115.45 Million
≈ $16.89 Million
0.245x -10.41%
2018-12-31 CN¥357.68 Million
≈ $52.34 Million
CN¥97.97 Million
≈ $14.34 Million
0.274x +8.12%
2017-12-31 CN¥440.76 Million
≈ $64.50 Million
CN¥111.66 Million
≈ $16.34 Million
0.253x +134.16%
2016-12-31 CN¥363.15 Million
≈ $53.14 Million
CN¥39.29 Million
≈ $5.75 Million
0.108x --

About Jiangsu Jibeier Pharmaceutical Co Ltd

SHG:688566 China Drug Manufacturers - Specialty & Generic
Market Cap
$791.60 Million
CN¥5.41 Billion CNY
Market Cap Rank
#10092 Global
#2697 in China
Share Price
CN¥26.90
Change (1 day)
+0.79%
52-Week Range
CN¥23.10 - CN¥35.75
All Time High
CN¥51.60
About

Jiangsu Jibeier Pharmaceutical Co., Ltd., a pharmaceutical company, engages in the drug research and development and production in China. The company's products cover multiple therapeutic areas such as increasing white blood cells, fighting hypertension, enhancing immunity, treating joint diseases, fighting eye infections, treating bronchitis, protecting liver function, etc. It is also developing… Read more